QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers
BRISBANE, 25 March 2025
QBiotics Group Limited (QBiotics) is pleased to announce it has appointed Jefferies (Australia) Pty Ltd (Jefferies) and Bell Potter Securities Limited (Bell Potter) as Joint Lead Managers (JLMs) to advise upon and assist QBiotics with a potential initial public offering (IPO) on the Australian Securities Exchange (ASX) this calendar year.
QBiotics Non-Executive Chairman, Mark Fladrich commented, “We are pleased to be taking the next step toward a potential ASX listing. This reflects the dedication of our entire team, and I want to acknowledge our co-founders, Dr Victoria Gordon and Dr Paul Reddell for their vision and leadership. Their contributions have been instrumental in bringing us to this stage.”
QBiotics CEO and Managing Director, Stephen Doyle commented, “The appointment of Jefferies and Bell Potter as Joint Lead Managers is a sign of our commitment to move towards a potential ASX listing. Jefferies and Bell Potter bring deep healthcare expertise, strong institutional relationships and a global investor network. We are pleased to be working closely together on this process.”
Shareholders should note the appointment of JLMs (or any other professional advisors) does not guarantee that an IPO will proceed. Any decision including the timing of the IPO will be made in due course, subject to market conditions and other relevant factors.
The Company remains committed to keeping shareholders informed as developments arise.
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company specialising in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate is currently in human clinical Phase II trials in Soft Tissue Sarcoma and Head and Neck Cancer. Tigilanol tiglate has received Orphan Drug Designation from the US FDA for the treatment of Soft Tissue Sarcomas. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013, is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.